David A. Siegel Tenaya Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tenaya Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 76,400 shares of TNYA stock, worth $127,588. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76,400
Previous 80,000
4.5%
Holding current value
$127,588
Previous $248,000
40.73%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TNYA
# of Institutions
96Shares Held
56.3MCall Options Held
900Put Options Held
400-
Column Group LLC San Francisco, CA9.4MShares$15.7 Million26.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.98MShares$11.7 Million0.19% of portfolio
-
Casdin Capital, LLC New York, NY6.73MShares$11.2 Million1.01% of portfolio
-
Black Rock Inc. New York, NY4.07MShares$6.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$5.37 Million0.0% of portfolio
About Tenaya Therapeutics, Inc.
- Ticker TNYA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,364,700
- Market Cap $69.1M
- Description
- Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hyp...